The COVID ‐19 chemoprophylactic conundrum: Are we limiting available resources?

Cathepsin inhibitors as potent inhibitors against SARS-CoV-2 main protease. In silico molecular screening and toxicity prediction

“…Research for effective drugs is focused on existing molecules already used as drugs in human or animal pharmacopeia, but also on mole cules not known for their antiviral effectiveness. The most effective treatments which have given interesting results are based on the use of Chloroquine and Hydroxychloroquine by blocking viral entry into cells and inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidificationB [10][11][12][13][14] Hydroxy-chloroquine and Azithromycin with antiviral molecules such like Lopinavir and Rotonavir are used combined in the Kaletra® [15] These agents also have immu-doi: https://doi.org/10.15407/ubj95.01.090 nomodulatory effects by attenuating the production of cytokines and inhibiting autophagy and lysosomal activity in host cells [16]. The pharmacopeia encompasses thousands of molecules that can be tested [17] to limit the replication of the virus and boost immune functions, such as Ivermectin® [18], but the time available means that we have to focus on some of them, of which we already suspect the probable effectiveness against the coronavirus.…”